In an MPO–AAV mouse model, treatment with Alvelestat and Bay 85–8501 successfully reduced NET accumulation in glomeruli and MPO deposition, resulting in reduced glomerular injury and decreased clustering of CD4 T cells, CD8 T cells, macrophages, and neutrophils in glomeruli, thus inhibiting the progression of MPA and renal damage. The gene discussed is MPO; the disease is microscopic polyangiitis.